CORFLOW Secures $48.6 Million in Series B Funding to Revolutionize Cardiac Care with Groundbreaking Microvascular Solutions

CorFlow, a pioneering Swiss medtech company dedicated to revolutionizing cardiac care, proudly announces it has successfully raised an impressive $48.6 million in its latest funding round. Established in 2016, CorFlow operates with the fundamental belief that current methods of diagnosing and treating cardiac issues fall short, particularly in identifying and addressing microvascular dysfunction. The company’s innovative approach underscores the vital need for diagnostic and therapeutic solutions centering around microvascular obstruction (MVO), a critical yet often overlooked component in improving patient outcomes during percutaneous coronary interventions (PCI). This newly acquired capital is set to advance CorFlow's mission of addressing unmet medical needs and will primarily be utilized for the development and clinical validation of the company's groundbreaking technology that aims to diagnose MVO in real time during PCI procedures. As clinical studies progress, CorFlow's platform positions itself not only as a diagnosis tool but also as a comprehensive treatment solution within cath labs. Under the leadership of CEO Paul Mead, who brings nearly 20 years of experience in the medtech industry, and with the support of an accomplished board, including Chairman and CEO of Cyrano Therapeutics, Rick Geoffrion, CorFlow is poised to lead the charge in enhancing cardiac and microvascular care. This funding marks a pivotal step towards their vision of restoring healthy microvascular blood flow and ultimately improving the quality of life for patients globally.